Search clinical trials for: determine the immune reactivity of biofilms in mesh erosion

Total 490194 results

Chang Gung Memorial Hospital
National Science Council, Taiwan

Unknown

The Immune Reactivity of Biofilms in Vaginal Mesh Erosion.

Urinary Incontinence | Uterine Prolapse | Fecal Incontinence

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) (CONCERTO)

Early Rheumatoid Arthritis

United States, Argentina, Austria, Belgium, Canada, Czech Republic, Germany, Poland, Puerto Rico, Spain
ITM Solucin GmbH

Not yet recruiting

Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (KinLET)

Lymphoma | CNS Tumor | Solid Tumor, Childhood | Somatostatin Receptor Positive | NET
Sunhawk Vision Biotech, Inc.

Not yet recruiting

Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients

Corneal Erosion

Taiwan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
University Hospital, Montpellier

Recruiting

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? (CARTROG)

Diffuse Large B Cell Lymphoma

France
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
University of Toronto

Recruiting

Modified Breath Test to Determine Anabolic Sensitivity Across Physical Activity States (BTLP)

Physical Inactivity | Resistance Exercise | Amino Acids | Dietary Protein

Canada
Møreforsking AS
University of Manchester; Helse Møre og Romsdal HF; Epax Norway AS

Recruiting

Nutritional Study to Determine the Effect of Fish Oil on Atopic Dermatitis (CetoSkin)

Atopic Dermatitis

Norway
Mayo Clinic

Recruiting

A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

Multiple Myeloma

United States
Vanderbilt-Ingram Cancer Center
Genentech, Inc.

Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT)

Stage IV Lung Cancer | Extensive Stage Lung Small Cell Carcinoma

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid Tumors

Australia, United States, Canada
All India Institute of Medical Sciences, Bhubaneswar

Recruiting

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

Bullous Pemphigoid

India
Al-Azhar University

Recruiting

Movement Disorders in Multiple Sclerosis Patients

Multiple Sclerosis | Movement Disorders

Egypt
Chinese University of Hong Kong

Recruiting

Effect of JAK Inhibitor on Erosion Healing in RA

Rheumatoid Arthritis

Hong Kong
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE)

Glioma | Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Brain Neoplasms | Solid Tumor | Malignant Neoplasm | Malignancy | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)

Glioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological Malignancy

United Kingdom
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Indiana University
National Institute of General Medical Sciences (NIGMS)

Recruiting

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

Melanoma | Non Small Cell Lung Cancer

United States
Samara State Medical University

Recruiting

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Endothelial Dysfunction | Cardiotoxicity | Acute Myeloid Leukemia, Adult

Russian Federation
Hoffmann-La Roche

Recruiting

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (ORIGAMA)

Cancer

Australia, Austria, Germany, Spain, Switzerland, Norway
Poitiers University Hospital

Recruiting

Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department (EOLE)

Moderate Asthma Exacerbation | Severe Asthma Exacerbation

France
Eli Lilly and Company

Recruiting

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

Breast Neoplasms

China, Japan, United States, Australia, Taiwan, Belgium, Canada, United Kingdom, Spain, France, Argentina, Ireland, Netherlands, Turkey, Czechia, Korea, Republic of, Finland, Hungary, Italy, Mexico, Brazil, Germany, India, Austria, Greece, Roman... and more
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
Shanghai Henlius Biotech

Recruiting

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Extensive Stage Small Cell Lung Cancer

United States
Lille Catholic University

Recruiting

Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders (SAMED)

Ehlers Danlos Hypermobile Syndrome

France
Amgen

Recruiting

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Taiwan, Switzerland, Spain, Canada, Israel, Germany, France, Belgium, Australia, Japan, Italy, Denmark
The Hospital for Sick Children

Recruiting

Comparison of Histology From a Mesh Sponge and Traditional Esophageal Biopsies in Children and Adolescents With EoE

Eosinophilic Esophagitis

Canada
ANRS, Emerging Infectious Diseases
Gilead Sciences

Not yet recruiting

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

HIV-1-infection

France
ABL Bio, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
University Health Network, Toronto
Bristol-Myers Squibb

Recruiting

Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT)

Non Small Cell Lung Cancer | Circulating Tumor DNA | Complete Surgical Resection

Canada
Georgetown University
Genentech, Inc.

Recruiting

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Non-squamous Non-small-cell Lung Cancer

United States
EMD Serono Research & Development Institute, Inc.

Recruiting

Next-Gen MS: Feed-forward PRO Data for MS Research

Multiple Sclerosis (MS)

United States
Hospital Civil de Guadalajara

Not yet recruiting

Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. (BERMESyH)

Metabolic Syndrome | Dyslipidemias | Glucose Intolerance | HIV-1-infection | Lipodystrophy | Lipoatrophy
German Cancer Research Center
Charite University, Berlin, Germany; Roche Pharma AG; Johannes Gutenberg University... and other collaborators

Recruiting

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3)

Newly Diagnosed H3-mutated Glioma

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Hepatocellular Carcinoma

Austria, Germany, Spain, Japan, Italy, France
Abbott

Recruiting

A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) (STRI)

Healthy | Hypothyroidism

India
Hoffmann-La Roche

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Solid Tumors

Belgium, United States, Australia, Canada, Japan, Korea, Republic of, United Kingdom, Germany, Taiwan, China, Puerto Rico, Israel, Singapore, Spain, Brazil, Portugal, South Africa, Denmark, Italy, Poland, Hong Kong, France, New Zealand and more
University of Bonn

Recruiting

Precision Immunology to Determine the Immune Response in Patients With COVID-19

SARS-CoV 2 | COVID

Germany
Deepak Kilari
Genentech, Inc.; Medical College of Wisconsin; Exelixis

Recruiting

Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

Bladder Cancer

United States
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Lawrence Fong
National Cancer Institute (NCI); Genentech, Inc.; The V Foundation; Conquer Cancer... and other collaborators

Completed

Neoadjuvant Atezolizumab in Localized Bladder Cancer

Carcinoma, Transitional Cell

United States
Sumitomo Pharma America, Inc.
Syneos Health

Terminated

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Neoplasms

United States
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China

Search clinical trials for: determine the immune reactivity of biofilms in mesh erosion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations